BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Nordic AML Group - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.namlg.org
X-WR-CALDESC:Events for Nordic AML Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260317T170000
DTEND;TZID=Europe/Paris:20260317T180000
DTSTAMP:20260415T215749
CREATED:20260216T121257Z
LAST-MODIFIED:20260216T121257Z
UID:10000035-1773766800-1773770400@www.namlg.org
SUMMARY:Webinar - Ask the expert: FLT3 MRD testing in AML patients
DESCRIPTION:Take the chance to join an Astellas Pharma sponsored webinar with Dr. Mark J. Levis\, MD\, PhD\, Baltimore\, USA\, entitled Ask the expert: FLT3 MRD testing in AML patients via Teams with the following agenda: \nAssess the current minimal residual disease testing modalities/methods\n Evaluate appropriate timing and efficacy of different FLT3 MRD testing modalities\n Summarize the appropriate treatment strategies in a post-transplant setting\n Best practice sharing in developing/setting up FLT3 MRD testing \nMore info and register here.
URL:https://www.namlg.org/event/webinar-ask-the-expert-flt3-mrd-testing-in-aml-patients/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260305T150000
DTEND;TZID=Europe/Paris:20260305T160000
DTSTAMP:20260415T215749
CREATED:20260304T002545Z
LAST-MODIFIED:20260304T002615Z
UID:10000036-1772722800-1772726400@www.namlg.org
SUMMARY:Germline Predisposition to Myeloid Neoplasms - Case discussions
DESCRIPTION:Join the MDR for patients with germline predisposition for hematological malignancies. \nThis meeting is for clinicians within the Nordics via this Zoom-link. \nIf you want to discuss a case\,  please send 1-2 summary slides with the most important information to Panagiotis Baliakas (panagiotis.baliakas@igp.uu.se)\, Uppsala\, Sweden. \n 
URL:https://www.namlg.org/event/germline-predisposition-to-myeloid-neoplasms-case-discussions/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260303T160000
DTEND;TZID=Europe/Paris:20260303T170000
DTSTAMP:20260415T215749
CREATED:20251128T074113Z
LAST-MODIFIED:20251128T074113Z
UID:10000030-1772553600-1772557200@www.namlg.org
SUMMARY:NAMLG – Steering group meeting
DESCRIPTION:Agenda and meeting link will be sent via e-mail.
URL:https://www.namlg.org/event/namlg-steering-group-meeting-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260226T140000
DTEND;TZID=Europe/Paris:20260226T151500
DTSTAMP:20260415T215749
CREATED:20260123T135454Z
LAST-MODIFIED:20260123T144130Z
UID:10000033-1772114400-1772118900@www.namlg.org
SUMMARY:Webinar - Innovations in AML care: Integrating Novel Treatments into Nordic Practice
DESCRIPTION:The Nordic AML Group’s Educational Working Group invites you to a scientific webinar focusing on recent innovations in the treatment of AML and their implementation in Nordic clinical practice. \nThe webinar will feature three expert speakers covering: \n– The evolving AML treatment landscape by professor Gail Roboz (New York) \n– Early Nordic experience with new AML therapies and ongoing Nordic studies by professor Bjørn Tore Gjertsen (Bergen) \n– Access pathways and future developments in AML care by associate professor Anne Louise Tølbøll Sørensen (Copenhagen) \nAim: To provide a clinically relevant and up-to-date overview of emerging therapeutic approaches for AML\, with particular emphasis on feasibility\, relevance\, and early adoption within the Nordic region. \nFormat: Webinar via Zoom via this link \nSponsorship: Sponsored by Otsuka. The sponsor has no influence on the scientific content or agenda. \n################################# \nAgenda – 2026-02-26 – 14:00 – 15:15 (CET) \n14:00 – 14:05 – Welcome & Introduction \n14:05 – 14:20 – The Evolving AML Landscape\, Professor Gail Roboz (New York) \n14:20 – 14:35 – From Data to Practice: Early Nordic Experience with New AML Treatments\, Professor Bjørn Tore Gjertsen (Bergen) \n14:35 – 14:45 – Discussion \n14:45 – 15:00 – Ongoing Nordic Studies\, Access Pathways\, and What’s Coming Next\, Associate professor Anne Louise Tølbøll Sørensen (Copenhagen) \n15:00 – 15:10 – Discussion \n15:10 – 15:15 – Closing remarks \n################################# \n 
URL:https://www.namlg.org/event/webinar-innovations-in-aml-care/
LOCATION:https://www.namlg.org/event/webinar-innovations-in-aml-care/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260120T150000
DTEND;TZID=Europe/Paris:20260120T190000
DTSTAMP:20260415T215749
CREATED:20260108T182048Z
LAST-MODIFIED:20260108T182048Z
UID:10000032-1768921200-1768935600@www.namlg.org
SUMMARY:Best of ASH 2025 by Lund
DESCRIPTION:At Best of ASH 2025\, hematologists in Lund\, Sweden present their top picks from the annual meeting of the American Society of Hematology (ASH) cutting through the volume to focus on data that change how we treat patients. Expect concise\, expert-led updates on key trials\, late-breaking abstracts\, and their real-world implications across hematology. \nLive on YouTube: https://www.youtube.com/live/DJrW-8hEHvI
URL:https://www.namlg.org/event/best-of-ash-2025-by-lund/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260113T160000
DTEND;TZID=Europe/Paris:20260113T170000
DTSTAMP:20260415T215749
CREATED:20251128T073938Z
LAST-MODIFIED:20251128T073938Z
UID:10000029-1768320000-1768323600@www.namlg.org
SUMMARY:NAMLG - Steering group meeting
DESCRIPTION:Agenda and meeting link will be sent via e-mail.
URL:https://www.namlg.org/event/namlg-steering-group-meeting/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20251217T150000
DTEND;TZID=Europe/Paris:20251217T170000
DTSTAMP:20260415T215749
CREATED:20251205T081747Z
LAST-MODIFIED:20251205T082100Z
UID:10000031-1765983600-1765990800@www.namlg.org
SUMMARY:Personalized Medicine in the Treatment of AML
DESCRIPTION:Jazz Pharmaceuticals is pleased to invite hematologists from the Nordic AML Group to join a distinguished academic webinar featuring Prof. Dr. med. Lars Bullinger and Prof. Bjørn Tore Gjertsen\, two leading experts in hematology and leukemia research. \nFind more info using this link. \nRegister using this QR code
URL:https://www.namlg.org/event/personalized-medicine-in-the-treatment-of-aml/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250911
DTEND;VALUE=DATE:20250913
DTSTAMP:20260415T215749
CREATED:20240425T112440Z
LAST-MODIFIED:20240425T112440Z
UID:10000013-1757548800-1757721599@www.namlg.org
SUMMARY:Nordic AML Meeting 11-12 September 2025
DESCRIPTION:Save the dates for the upcoming Nordic AML Meeting in Bergen\, Norway\, 2025.
URL:https://www.namlg.org/event/nordic-aml-meeting-11-12-september-2025/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250910T200000
DTEND;TZID=Europe/Paris:20250910T213000
DTSTAMP:20260415T215749
CREATED:20250813T190033Z
LAST-MODIFIED:20250827T111558Z
UID:10000025-1757534400-1757539800@www.namlg.org
SUMMARY:Presentation of a Nordic platform for future collaborative projects on TP53 mutated myeloid malignancies
DESCRIPTION:It’s an open meeting for clinicians and preclinical researchers but meant for those that are actually interested to take part in future Nordic collaborative TP53 related myeloid research. \nThe meeting will be held at Hotel Norge\, Bergen\, in connection with the NAMLG meeting\, Room number will be announced at the hotel reception. \nThe meeting will also be possible to attend by Zoom. \nChair: Professor Sören Lehmann\, Sweden \n 
URL:https://www.namlg.org/event/presentation-of-a-nordic-platform-for-future-collaborative-projects-on-tp53-mutated-myeloid-malignancies/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250910
DTEND;VALUE=DATE:20250911
DTSTAMP:20260415T215749
CREATED:20240804T182910Z
LAST-MODIFIED:20240804T182957Z
UID:10000015-1757462400-1757548799@www.namlg.org
SUMMARY:AML Course Day 10 September 2025
DESCRIPTION:The Educational Working Group is planning an “AML Course Day” in conjunction with the Nordic AML Meeting in Bergen 2025. \nThe AML Course Day covers topics such as the current diagnostics and therapeutics\, the latest with regard to MRD as well as clinically inclined discussions on emergencies and infectious problems in AML. \nThe AML Course Day will be open for registration for physicians in the Nordics who take care of patients with AML. \nMore information is coming\, but save-the-date!
URL:https://www.namlg.org/event/aml-course-day/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250513
DTEND;VALUE=DATE:20250515
DTSTAMP:20260415T215749
CREATED:20250307T052039Z
LAST-MODIFIED:20250307T052103Z
UID:10000023-1747094400-1747267199@www.namlg.org
SUMMARY:The 13th CCBIO Annual Symposium
DESCRIPTION:CCBIO has the pleasure of inviting you to the 13th CCBIO Annual Symposium May 13-14\, and now\, PREFINAL PROGRAM is available. \nTo participate\, please register within April 1. \nThere will be a strong scientific program including a range of international speakers\, among them Sir David Lane\, Eva Hellström-Lindberg\, Theodoros Foukakis\, Anna Dimberg\, Steinar Ø. Thoresen\, Gema Moreno-Bueno and Jean Albrengues.
URL:https://www.namlg.org/event/the-13th-ccbio-annual-symposium/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250513
DTSTAMP:20260415T215749
CREATED:20250307T052248Z
LAST-MODIFIED:20250307T052248Z
UID:10000024-1747008000-1747094399@www.namlg.org
SUMMARY:The c-myc Single Cell Satellite Seminar
DESCRIPTION:The newly established Jebsen Centre for Myeloid Blood Cancer (c-myc) will have their first Annual c-myc Seminar as a full-day satellite to CCBIO’s 13th Annual Symposium and will showcase recent advancements in single-cell genomics\, transcriptomics\, proteomics\, and preclinical trials\, setting the stage for future clinical applications. The event will bring together leading researchers to explore how single-cell resolution can advance cancer treatment and improve patient outcomes. For program\, registration and practical information\, please consult the seminar website.
URL:https://www.namlg.org/event/the-c-myc-single-cell-satellite-seminar/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250317T120000
DTEND;TZID=Europe/Paris:20250317T140000
DTSTAMP:20260415T215749
CREATED:20250307T051600Z
LAST-MODIFIED:20250307T051600Z
UID:10000022-1742212800-1742220000@www.namlg.org
SUMMARY:NAMLG Lunch Meeting in Munich
DESCRIPTION:For Nordic AML physicians attending the Acute Leukemia Symposium ISALXIX in Munich 16-19th March 2025\, You are cordially invited to a NAMLG Lunch Meeting in\non Monday March 17th\, 12.00-14.00. Find more info in this flyer. [With support from Servier and the organizing committee in Munich.]
URL:https://www.namlg.org/event/namlg-lunch-meeting-in-munich/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20241207T070000
DTEND;TZID=America/Los_Angeles:20241207T090000
DTSTAMP:20260415T215749
CREATED:20241129T210823Z
LAST-MODIFIED:20241129T210823Z
UID:10000021-1733554800-1733562000@www.namlg.org
SUMMARY:NAMLG Breakfast Meeting @ ASH
DESCRIPTION:You are cordially invited to the NAMLG Breakfast Meeting\, held during ASH in San Diego. \nDate: Saturday\, December 7th\nTime: 7:00 AM – 9:00 AM \nThis event is generously sponsored by AbbVie. \nTo register\, please contact Bjørn Tore Gjertsen (Bjorn.Gjertsen@uib.no).
URL:https://www.namlg.org/event/namlg-breakfast-meeting-ash/
LOCATION:675 L St\, San Diego\, CA 92101\, USA\, 675 L Street\, San Diego\, CA\, 92101\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241121T120000
DTEND;TZID=Europe/Paris:20241121T170000
DTSTAMP:20260415T215749
CREATED:20241029T114558Z
LAST-MODIFIED:20241029T114558Z
UID:10000020-1732190400-1732208400@www.namlg.org
SUMMARY:MNSCT 2024 Meeting
DESCRIPTION:MNSCT 2024 Meeting  \nDate: 21 November 2024 \nVenue: Grand Hotel\, Lund\, Sweden or online \nRegistration: https://mkon.nu/mnsct_2024/registration \nProgram \n12:00-12:55   Lunch\, registration starts at 11.45 \n13:00-13:05   Welcome/Introduction  (Assoc. Prof. Andreas Björklund\, Stockholm\, Assoc. Prof. Jörg Cammenga\, Lund) \nSession 1:             \n13:05-13:45   Prof. Dr. Thomas Schröder\, University Hospital Essen\, Essen Germany — “Pharmacological preemptive and prophylactic approaches to prevent/treat relapse of   myeloid neoplasms after allo SCT” \n13:40-14:20  Assoc. Professor Dr. Luca Vago\, Milan\, Italy — “Mechanisms of immune escape after allogeneic stem cell transplantation” \n14:20-14:30   Coffee break \nSession 2:              \n14:30-15:10   Ass. Professor Dr. A\, Mishra\, MD (Tampa\, Florida) — “Targeted agents post- allo HSCT based on mutational status” \n15:15-15:55  Ass. Professor Dr. Jacqueline S. Garcia\, MD  (Harvard Medical School\, Dana-Farber Cancer Institute) — “Post transplant maintenance: Finding the sweet spot” \n16:00-16:55  Plenary discussion (all speakers (virtual/local) + moderators) \n16:55-17:00  Closing remarks
URL:https://www.namlg.org/event/mnsct-2024-meeting/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241121T000000
DTEND;TZID=Europe/Paris:20241121T130000
DTSTAMP:20260415T215749
CREATED:20241024T062828Z
LAST-MODIFIED:20241024T062828Z
UID:10000019-1732147200-1732194000@www.namlg.org
SUMMARY:mIDH1-mutated AML: ivosidenib in clinical practice
DESCRIPTION:This Servier arranged webinar is for hematologists. The agenda for the webinar is: \n12:00-12:05 – Introduction by Erik Holgén\, Product Manager\, Servier \n12:05-12:30 – Prof. Dr. Michael Heuser – Will present the AGILE study and the clinical implications of the study results. \n12:30-12:45 – Docent Vladimir Lazarevic – Focusing on treatment of mIDH1 AML patients in the future \n12:45-13:00 – Questions & Answers \n——————- \nUnable to attend at this time? Register anyway to receive the recording afterwards. \nClick here to register
URL:https://www.namlg.org/event/midh1-mutated-aml-ivosidenib-in-clinical-practice/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241029T160000
DTEND;TZID=Europe/Paris:20241029T180000
DTSTAMP:20260415T215749
CREATED:20241007T174955Z
LAST-MODIFIED:20241007T174955Z
UID:10000018-1730217600-1730224800@www.namlg.org
SUMMARY:Evolving treatment options for patients with AML ineligible for intensive chemotherapy
DESCRIPTION:Find more info in this flyer. \nLocation: Aarhus University Hospital AUH SYD\, auditorium C114-101. Indgang C\, C110 or join online. \n\n\n\n\n\nPlease send your registration for the meeting before October 16th to Daniel Tuyet Kristensen (dankrt@rm.dk). Please note if you will participate in person or online to receive a link.
URL:https://www.namlg.org/event/evolving-treatment-options-for-patients-with-aml-ineligible-for-intensive-chemotherapy/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240924T150000
DTEND;TZID=Europe/Paris:20240924T163000
DTSTAMP:20260415T215749
CREATED:20240804T181813Z
LAST-MODIFIED:20240829T085437Z
UID:10000014-1727190000-1727195400@www.namlg.org
SUMMARY:Webinar - Azacitidine-Venetoclax: latest clinical updates
DESCRIPTION:The NAMLG’s Educational Working Group is hosting a webinar on September 24\, 2024\, from 15:00 to 16:30 CEST. The webinar will provide the latest insights on using Aza-Ven in AML treatment including discussions from a Nordic perspective. Topics will include its application as a first-line treatment\, dosing optimizations\, and strategies for maintenance therapy. \nYou can find the program here. \nThere is no registration required as the webinar will be sent via Zoom\, see the program for details and passcode. \nThe webinar is supported by AbbVie and the KG Jebsen Centre for Myeloid Blood Cancer at the University of Bergen.
URL:https://www.namlg.org/event/webinar-azacitidine-venetoclax-latest-clinical-updates/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240913T093000
DTEND;TZID=Europe/Paris:20240913T153000
DTSTAMP:20260415T215749
CREATED:20240912T141316Z
LAST-MODIFIED:20240912T141524Z
UID:10000017-1726219800-1726241400@www.namlg.org
SUMMARY:Workshop & Talks: Nanopore Sequencing Technologies
DESCRIPTION:Find more information via this link.\n\nJoin the workshop online\, by using this Zoom link: \nhttps://nanoporetech.zoom.us/j/88211217159?pwd=vlPpfbolZ8bd9kQgQ4Vdi5kytU7Bbb.1 \nPasscode: 145047 \n\nor join in place at this location:\n\nAuditorium 2 & 4\, BB-Bygget. Haukeland Universitetssykehus – Jonas Lies vei 91. 5009 Bergen
URL:https://www.namlg.org/event/workshop-talks-nanopore-sequencing-technologies/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240911
DTEND;VALUE=DATE:20240913
DTSTAMP:20260415T215749
CREATED:20240829T070254Z
LAST-MODIFIED:20240829T070254Z
UID:10000016-1726012800-1726185599@www.namlg.org
SUMMARY:Opening Symposium of the KG Jebsen Centre for Myeloid Blood Cancer\, C-MYC\, in Bergen
DESCRIPTION:Join the opening symposium of the new KG Jebsen Centre for Myeloid Blood Cancer\, C-MYC\, on September 11 and 12\, 2024 in Bergen! \nFind the program and register using this link.
URL:https://www.namlg.org/event/opening-symposium-of-the-kg-jebsen-centre-for-myeloid-blood-cancer-c-myc-in-bergen/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240615T113000
DTEND;TZID=Europe/Paris:20240615T133000
DTSTAMP:20260415T215749
CREATED:20240425T111615Z
LAST-MODIFIED:20240613T174549Z
UID:10000010-1718451000-1718458200@www.namlg.org
SUMMARY:EHA Meeting: Nordic Lunch meeting
DESCRIPTION:NAMLG lunch meeting to be held in Sponsor Meeting Hub (in Hall 9) between 11:30 and 13:30 on Saturday 15th June. \nPreliminary agenda \n\n11:30-11:35: Welcome\, v. Bjørn-Tore Gjertsen\, Chairman\n11:35-11:45 Remarks from the sponsor v. Delbert Pharma\n11:45-12:25: NAMLG activities:\n\n11:45-11:55: Scientific working group\, Sören Lehmann\n11:55-12:05: Educational working group\, Albin Österroos/Daniel Tuyet Kristensen\n12:05-12:25: Trial working group\, Bjørn Tore Gjertsen\n\nDrug repurposing trials in RR AML: Melphalan for hypoplastic AML / DDX41 mutated (Jakob Dalgaard)\nHUVAMER and Early response evaluation (Bjørn Tore Gjertsen)\n\n\n\n\n\n\n12:25-12:55: Diagnostic working group\, Linda Fogelstrand\n12:55-13:05: About the 2025 biannual NAMLG meeting\, Björn Tore Gjertsen\n13:05-13:10: Steering group meeting schedule for 2024/2025\, Daniel Tuyet Kristensen\n13:10-13:30: Any other business and mingle with colleagues\n\nFor the Teams link\, please contact Daniel (dakr@dcm.aau.dk) or Albin (albin.osterroos@medsci.uu.se). \nPlease\, find more info at Invitation letter – NAMLG lunch – Madrid 2024.
URL:https://www.namlg.org/event/eha-meeting-nordic-lunch-meeting/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240508T150000
DTEND;TZID=Europe/Paris:20240508T160000
DTSTAMP:20260415T215749
CREATED:20240425T111839Z
LAST-MODIFIED:20240425T111839Z
UID:10000011-1715180400-1715184000@www.namlg.org
SUMMARY:NAMLG Educational Working Group meeting
DESCRIPTION:Join via Teams using this link.
URL:https://www.namlg.org/event/namlg-educational-working-group-meeting/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240506T153000
DTEND;TZID=Europe/Paris:20240506T163000
DTSTAMP:20260415T215749
CREATED:20240425T112303Z
LAST-MODIFIED:20240426T072208Z
UID:10000012-1715009400-1715013000@www.namlg.org
SUMMARY:Nordic MPAL meeting
DESCRIPTION:For more information\, please contact Vladimir Lazarevic\, Lund\, Sweden. \nJoin via Teams using this link. \n 
URL:https://www.namlg.org/event/nordic-mpal-meeting/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240321T143000
DTEND;TZID=Europe/Paris:20240321T153000
DTSTAMP:20260415T215749
CREATED:20240312T151714Z
LAST-MODIFIED:20240312T151844Z
UID:10000009-1711031400-1711035000@www.namlg.org
SUMMARY:CCBIO Seminar – Mika Kontro - Functional Screening for Precision Medicine Approaches in AML
DESCRIPTION:Dr. Mika Kontro will discuss the methods for personalizing AML therapies using functional screening. He will provide an overview of the current data implementation and share insights from ongoing prospective trials employing functional screening. Furthermore\, Dr. Kontro will focus on the VenEx trial\, which utilizes ex vivo drug sensitivity testing to identify AML patients who can benefit from the azacitidine-venetoclax regimen. \nMore info can be found on this link. \nJoin via Zoom using this link. \nNo registration necessary.
URL:https://www.namlg.org/event/ccbio-seminar-mika-kontro-functional-screening-for-precision-medicine-approaches-in-aml/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240312T150000
DTEND;TZID=Europe/Paris:20240312T170000
DTSTAMP:20260415T215749
CREATED:20240213T194106Z
LAST-MODIFIED:20240304T122131Z
UID:10000008-1710255600-1710262800@www.namlg.org
SUMMARY:Nordic AML 'poster walk' post-ASH
DESCRIPTION:Nordic AML posters at ASH 2023 – Webinar – 2024-03-12 – 15:00-16:20 (CET) \nJoin us for a webinar where we delve into the intricacies of showcased Nordic AML posters at the latest ASH Annual Meeting in December 2023. Here we aim for an opportunity to gain valuable insights\, connect with peers\, and stay at the forefront of AML innovation. \n\nJoin via Zoom: https://uu-se.zoom.us/j/63956689621 \n\nTentative agenda (updated 2024-03-04) \n15:00 – 15:05 – Welcome \n15:05 – 15:15 – Elory Leonard\, Stockholm\, Sweden \nProtective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells \n15:15 – 15:25 – Ida Vänttinen\, Helsinki\, Finland \nTargeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia \n15:25 – 15:35 – Claudia Schöllkopf\, Copenhagen\, Denmark \nDose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) \n15:35 – 15:45 – Sofie Johansson Alm\, Gothenburg\, Sweden \nDeep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1 \n15:45 – 15:55 – Øystein Sefland\, Bergen\, Norway \nIntradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site\, Visualized Using Imaging Mass Cytometry\, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses \n15:55 – 16:05 – Hanna Duàn\, Helsinki\, Finland \nPrimary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells \n16:05 – 16:15 – Somadri Ghosh\, Lund\, Sweden \nH2-K1 on MLL-AF9 Leukemia Cells Facilitates the Escape of NK Cell-Mediated Immune Surveillance \n16:15 – 16:25 – Jonas Bouhlal\, Helsinki\, Finland \nHigh-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers \n16:25 – 16:30 – Closing remarks \n\nArranged by the NAMLG Educational Working Group (namlgewg@gmail.com)
URL:https://www.namlg.org/event/nordic-aml-poster-walk-post-ash/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240125T160000
DTEND;TZID=Europe/Paris:20240125T170000
DTSTAMP:20260415T215749
CREATED:20240124T102108Z
LAST-MODIFIED:20240124T102108Z
UID:10000006-1706198400-1706202000@www.namlg.org
SUMMARY:Early Response Evaluation by Single-Cell Signaling Profiling in AML
DESCRIPTION:Webinar to be held January 25 at 16:00 \nThis is in Standard Biotools’ (former Fluidigm) Scientist in the Spotlight series. \nMore info and registration on this link. \nHear about: \nInsights into AML response: Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients. \n  \nPredicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort\, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation. \n  \nImportance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data and highlight the potential for this assay to be used in the future of precision oncology.
URL:https://www.namlg.org/event/early-response-evaluation-by-single-cell-signaling-profiling-in-aml/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240124T153000
DTEND;TZID=Europe/Paris:20240124T163000
DTSTAMP:20260415T215749
CREATED:20240124T110456Z
LAST-MODIFIED:20240124T110456Z
UID:10000007-1706110200-1706113800@www.namlg.org
SUMMARY:NAMLG TWG Meeting - I - 24-01-2024  15:30-16:30 CET
DESCRIPTION:Link and passcode for Teams meeting sent separately. \nAgenda: \n\nUpdate on potential LD-VenEx amendment trial comparing poDEC/LD-VenEx vs. AZA/LD-VenEx (5 min + 10 min discussion).\nNAMLG – platform trial structure concept (5 min): Infrastructure with standing collaboration contracts (clinical trial agreement – CTA) and data processing agreements (DPAs) applicable for all types of trials. This would allow to open trials at one Nordic sponsor site and recruit pts from all Nordic Sites without the requirement to establish new CTAs / DPAs for each trial with individually. Ultimately\, this will establish the NAMLG as partner for pharma-sponsored trials as well as to obtain funding for IIT.\nList/overview of ongoing\, already planned\, and potential future AML trials in the Nordics.\nPresentation and discussion of ongoing and potential novel AML trials\n\nMartin Jädersten – Salvage Treatment + HU (5 min + 5 min discission\nOxcia: Presentation of MAATEO Karonudib + Dauno for RR AML (7 min+ 3 min discussion)\nTrials suggested in previous mail by Bjørn Tore Gjertsen (6 min + 4 min discussion)
URL:https://www.namlg.org/event/namlg-twg-meeting-i-24-01-2024-1530-1630-cet/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231206T153000
DTEND;TZID=Europe/Paris:20231206T163000
DTSTAMP:20260415T215749
CREATED:20231201T074717Z
LAST-MODIFIED:20240316T192439Z
UID:10000005-1701876600-1701880200@www.namlg.org
SUMMARY:Webinar - Immunotherapy: a new perspective for AML maintenance treatment?
DESCRIPTION:Agenda \n[Post updated 2024-03-16] \nDownload a recorded version of the webinar using this link. \nFind the HCP guide for Ceplene on this link. \nCeplene can be ordered with the Nordic item number (Vnr.) 46 54 33\, through: \nOriola in Sweden\nTMJ in Denmark\nYour local wholesaler\, Apotek 1\, NMD and Alliance in Norway \n——————————————— \nAML patients not candidates to allotransplant: relapse risk and therapeutics (Pr Bjorn Gjertsen) \nImmunotherapy with Histamine dihydrochloride in association with low-dose interleukin-2 (HDC/IL-2) for relapse prevention (Pr Kristoffer Hellstrand) \nConceivable indications of HDC/IL-2 for post-remission in AML? (Pr Bjorn Gjertsen\, Dr Martin Jädersten\, Dr Lovisa Wennström) \nFor more info\, click here. \nFor registration\, click here.
URL:https://www.namlg.org/event/webinar-immunotherapy-a-new-perspective-for-aml-maintenance-treatment/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231130T120000
DTEND;TZID=Europe/Paris:20231130T210000
DTSTAMP:20260415T215749
CREATED:20231123T100038Z
LAST-MODIFIED:20231123T100446Z
UID:10000003-1701345600-1701378000@www.namlg.org
SUMMARY:Myeloid Neoplasia StemCellTransplant (MNSCT) Nordic workshop
DESCRIPTION:We are thrilled to invite you all to the first MNSCT workshop. The program is planned by a scientific committee from the Swedish-Norwegian BMT-group and the Swedish AML-group. The overarching aim of this meeting is to stimulate discussions around topics within the Nordic community. \nPlease register for this event using this link (deadline 2023-10-27). \nClick here for more information and the program. \nThe workshop is supported by medac Nordics.
URL:https://www.namlg.org/event/myeloid-neoplasia-stemcelltransplant-mnsct-nordic-workshop/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231108T080000
DTEND;TZID=Europe/Paris:20231108T170000
DTSTAMP:20260415T215749
CREATED:20231123T095916Z
LAST-MODIFIED:20231123T095916Z
UID:10000002-1699430400-1699462800@www.namlg.org
SUMMARY:Nordic AML webinar
DESCRIPTION:Thank you to all participants for taking part in the Nordic AML webinar 2023-11-08. For a recording of the webinar use this link.
URL:https://www.namlg.org/event/nordic-aml-webinar/
END:VEVENT
END:VCALENDAR